前列腺癌治疗的进展:前列腺癌的放射性核素治疗。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI:10.1016/bs.acr.2024.07.004
Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata
{"title":"前列腺癌治疗的进展:前列腺癌的放射性核素治疗。","authors":"Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata","doi":"10.1016/bs.acr.2024.07.004","DOIUrl":null,"url":null,"abstract":"<p><p>The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting <sup>177</sup>Lu-PSMA radionuclide therapy have demonstrated the utility of <sup>177</sup>Lu-PSMA in the treatment of mCRPC. Further research into alpha-emitting radionuclide therapy and vectors may provide alternative treatments for patients with treatment resistant mCRPC. As radionuclide therapy treatment options evolve, assessing appropriate patient selection for radionuclide therapy is important and may be facilitated by advances in imaging and blood-based biomarkers. Exploration of other approved life prolonging therapies in combination with radionuclide therapy has shown increasing interest as a potential method of combatting radionuclide therapy resistance. In this chapter, we review various types of radionuclide therapies for mCRPC, patient selection for radionuclide therapy from outcome predictions, ongoing clinical trials of radiopharmaceuticals for treatment of prostate cancer, and the resistance mechanisms and challenges to radionuclide therapy.</p>","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"311-358"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.\",\"authors\":\"Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata\",\"doi\":\"10.1016/bs.acr.2024.07.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting <sup>177</sup>Lu-PSMA radionuclide therapy have demonstrated the utility of <sup>177</sup>Lu-PSMA in the treatment of mCRPC. Further research into alpha-emitting radionuclide therapy and vectors may provide alternative treatments for patients with treatment resistant mCRPC. As radionuclide therapy treatment options evolve, assessing appropriate patient selection for radionuclide therapy is important and may be facilitated by advances in imaging and blood-based biomarkers. Exploration of other approved life prolonging therapies in combination with radionuclide therapy has shown increasing interest as a potential method of combatting radionuclide therapy resistance. In this chapter, we review various types of radionuclide therapies for mCRPC, patient selection for radionuclide therapy from outcome predictions, ongoing clinical trials of radiopharmaceuticals for treatment of prostate cancer, and the resistance mechanisms and challenges to radionuclide therapy.</p>\",\"PeriodicalId\":94294,\"journal\":{\"name\":\"Advances in cancer research\",\"volume\":\"164 \",\"pages\":\"311-358\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cancer research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.acr.2024.07.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.acr.2024.07.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

鉴于有多种延长生命的治疗方案,转移性抗性前列腺癌(mCRPC)的最佳治疗方法仍然具有挑战性。放射性核素疗法通过与具有特定肿瘤靶点的配体或抗体分子螯合的电离粒子提供集中剂量的辐射,已被批准用于治疗耐药 mCRPC 患者。目前正在对前列腺癌连续治疗过程中的各种放射性核素疗法进行研究。具有里程碑意义的β发射177Lu-PSMA放射性核素疗法III期临床试验证明了177Lu-PSMA在治疗mCRPC方面的实用性。对α-发射型放射性核素疗法和载体的进一步研究可能会为治疗耐药的mCRPC患者提供替代疗法。随着放射性核素疗法治疗方案的不断发展,评估适当的放射性核素疗法患者选择非常重要,而成像和血液生物标记物的进步可能会促进这种评估。作为消除放射性核素治疗耐药性的一种潜在方法,探索其他已获批准的延长生命疗法与放射性核素治疗的联合应用已显示出越来越大的兴趣。在本章中,我们将回顾治疗mCRPC的各类放射性核素疗法、从结果预测中选择接受放射性核素治疗的患者、正在进行的治疗前列腺癌的放射性药物临床试验,以及放射性核素疗法的耐药机制和挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.

The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting 177Lu-PSMA radionuclide therapy have demonstrated the utility of 177Lu-PSMA in the treatment of mCRPC. Further research into alpha-emitting radionuclide therapy and vectors may provide alternative treatments for patients with treatment resistant mCRPC. As radionuclide therapy treatment options evolve, assessing appropriate patient selection for radionuclide therapy is important and may be facilitated by advances in imaging and blood-based biomarkers. Exploration of other approved life prolonging therapies in combination with radionuclide therapy has shown increasing interest as a potential method of combatting radionuclide therapy resistance. In this chapter, we review various types of radionuclide therapies for mCRPC, patient selection for radionuclide therapy from outcome predictions, ongoing clinical trials of radiopharmaceuticals for treatment of prostate cancer, and the resistance mechanisms and challenges to radionuclide therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信